Clinical trialPhase 2Completed
Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer
A Phase II Trial of Erlotinib in Combination With Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer
- Outcome
- Finished, no results posted
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- June 2009
- Expected end
- May 2011
- Enrollment
- 22 participants
- Sites
- 3
- Primary outcomes
- To assess the response rate associated with gemcitabine, erlotinib and cisplatin in patients with advanced pancreatic cancer
- Sponsor
- Other
- Results posted
- No
- Last update
- 20 November 2012
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.
Papers 1
- Registry-listed results paperA phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. DOI 10.1007/s10637-012-9792-z↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.